Programmed death-1 inhibition and atherosclerosis: can nivolumab vanish complicated atheromatous plaques?

Ann Oncol. 2018 Jan 1;29(1):284-286. doi: 10.1093/annonc/mdx718.

Authors

F Gelsomino^{1

2}, M Fiorentino³, M Zompatori⁴, A Poerio⁴, B Melotti², F Sperandi², M Gargiulo⁵, C Borghi⁶, A Ardizzoni^{2

7}

Affiliations

¹ Medical Oncology, University Hospital of Parma, Parma, Italy.
² Medical Oncology Unit, Policlinico S.Orsola-Malpighi, Bologna, Italy.
³ Laboratory of Molecular Pathology, Addarii Institute of Oncology, Bologna, Italy.
⁴ Unit of Radiology, Policlinico S.Orsola-Malpighi, University of Bologna, Bologna, Italy.
⁵ Unit of Vascular Surgery, Policlinico S.Orsola-Malpighi, University of Bologna, Bologna, Italy.
⁶ Unit of Internal Medicine, Policlinico S.Orsola-Malpighi, University of Bologna, Bologna, Italy.
⁷ Unit of Medical Oncology, Policlinico S.Orsola-Malpighi, University of Bologna, Bologna, Italy.

PMID: 29106493
DOI: 10.1093/annonc/mdx718

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Atherosclerosis / drug therapy*
Atherosclerosis / immunology
Atherosclerosis / pathology
Humans
Nivolumab / therapeutic use*
Plaque, Atherosclerotic / drug therapy*
Plaque, Atherosclerotic / immunology
Plaque, Atherosclerotic / pathology
Programmed Cell Death 1 Receptor / antagonists & inhibitors*
Programmed Cell Death 1 Receptor / immunology

Substances

PDCD1 protein, human
Programmed Cell Death 1 Receptor
Nivolumab